PubMed Health⌕ Search

Biomedical subjects

I Raz

Publications and source records attributed to I Raz.

At least 127 records · Page 7Linked to original sources
PubMed1984

Hairy cell leukemia: report of an unusual case with hepatomegaly due to a large vascular tumor of the liver, mediastinal mass and pleural effusion containing hairy cells.

An unusual patient with hairy cell leukemia (HCL) who developed marked hepatomegaly due to a large vascular tumor in the liver is reported. The relation of this vascular tumor to the microscopic splenic pseudosinuses and hepatic angiomatous lesions encountered in HCL is discussed. To the best of our knowledge this represents the first case report of the association of HCL with large macroscopic hemangioma of the liver causing hepatomegaly. The patient also developed a large paratracheal mediastinal mass with a recurrent pleural effusion which was shown to contain many typical hairy cells. This rare finding is discussed in relation to the isolated cases of lymphocytic lymphoma who present with clinical and morphological features mimicking HCL. This patient had HCL according to all established criteria with characteristic morphological, cytochemical and ultrastructural features and the pleural effusion and mediastinal mass were most probably part of the HCL neoplasia, despite the fact that biopsy was not performed.

Female↗
PubMed1984

Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.

The pharmacokinetics and bioavailability of valproic acid (VPA) were compared in six healthy volunteers after oral administration of the drug as follows: 1 g in standard tablet form, 1 g in enteric-coated tablet form, and 0.8 g in gelatin-capsule form. Following the administration of standard tablets, VPA concentrations reached a peak mean +/- SD of 105.4 +/- 9.0 micrograms/ml at 1 h and declined monoexponentially, with a terminal half-life of 14.9 +/- 2.4 h. Following the administration of the capsule, the serum concentration reached a peak of 82.1 +/- 14.8 micrograms/ml at 4 h. Following the administration of an enteric-coated tablet, there was an average time lag of 2 h with a delayed peak serum concentration of 93.5 +/- 13.1 micrograms/ml at 6 h. An identical terminal half-life of VPA was obtained for the three oral formulations. The bioavailability of the three VPA formulations was not significantly different, and it may be concluded that these formulations are bioequivalent.

Administration, Oral↗
PubMed1981

Developmental differences in identifying and discriminating CV syllables.

The purpose of this experiment was to determine whether age-related differences would be observed for identification and discrimination of synthesized, five-formant CV syllables among listeners who showed equal performance scores on a standard clinical test of speech understanding. A second question concerned the relations between performance on identification and discrimination tasks as a function of age. Two 13-item continua that varied in the place of articulation feature ([ba, da, ga]) were used; they differed primarily in the presence of absence of a 5-ms noise burst at the consonant onset. Digitized natural speech syllables were also employed in one experimental task. Strong age effects were obtained for the three tasks--identification of syllables, adaptive estimation of "ba, da-" and "da, ga-" boundaries, and discrimination. With the exception of one condition for six-year-olds, only adults showed significant differences between boundaries and just noticeable differences. Minimal differences were obtained in responses to stimuli with and without initial bursts. Across ages there were no significant differences in the subjects' ability to label the synthesized syllables as compared to the natural speech stimuli. Possible explanations for the observed developmental effects are discussed.

Adult↗
PubMedDate not supplied

Pharmacokinetics of valproic acid in volunteers after a single dose study.

The pharmacokinetics of valproic acid (VPA) was investigated in six healthy volunteers. This was done by monitoring total and free (unbound) valproic acid levels in the serum, and the amount of one of its metabolites, VPA glucuronide, in the urine as a function of time, after a single dose administration of the parent drug. VPA half-life calculated from the urine data of the metabolite was shorter than the half-life calculated from the blood data. About 15 to 20 per cent of the administered oral dose of VPA was excreted in the urine as VPA glucuronide. The average free fraction of VPA obtained in this study, by using the EMIT technique, ranged from 1.5 to 11.5 per cent with a mean value of 4.9 per cent.

Adult↗
PubMedDate not supplied

Pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid in humans.

Five new sustained-release dosage forms of valproic acid (VPA) were developed. The new sustained-release formulations were administered to six healthy subjects for comparison with a standard tablet and an i.v. preparation of the drug. Three of the formulations exhibited a more prolonged and uniform absorption rate and yielded more sustained serum levels after ingestion. These three formulations maintained serum therapeutic levels of VPA for 24 h after a single oral administration of 1 g, and were bioequivalent to a marketed standard tablet of VPA. The absorption profile of the various oral formulations was analysed pharmacokinetically, using the Loo-Riegelman procedure.

Administration, Oral↗
PubMedDate not supplied

Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: comparison of single and multiple dose studies.

A pharmacokinetic analysis of two sustained-release dosage forms of theophylline (Theo-Dur and Theotrim) was carried out following single and multiple dose administrations of the two formulations in five healthy subjects. Despite the prolonged absorption after administration of the two sustained-release formulations, theoretical predictions of theophylline steady-state levels following multiple dosages based upon data obtained from the single dose study, correlated with the data of the multiple dose study. This study shows that the recommended dose and dosage regimen of new sustained-release formulations of theophylline can be based upon single dose studies. In the population studied, repetitive doses of 450 mg b.i.d. of Theo-Dur and Theotrim maintain steady-state concentrations of theophylline within the drug's therapeutic window.

Absorption↗
PubMedDate not supplied

Effect of moderate exercise on serum lipids in young men with low high density lipoprotein cholesterol.

Fifty-five healthy, sedentary, nonsmoking, and nonobese 24- to 26-year-old men who had low plasma concentrations of high density lipoprotein (HDL) cholesterol were selected for a study of the effect of short-term exercise on plasma lipid and lipoprotein concentrations. The participants were randomized into two groups. Of these, 28 were assigned to a 9-week program of submaximal aerobic exercise three times weekly, and 27 were assigned to a nonexercising control group. Changes in physical fitness were assessed by increments in estimated maximal oxygen consumption; this increased by 15% in the exercise group (p less than 0.001) but remained unchanged in the control group. During the study, body weights and skinfold thicknesses of both groups remained essentially unchanged after 9 weeks. There was no significant difference between the trial groups in total cholesterol, HDL cholesterol, calculated low density lipoprotein cholesterol, or in the HDL2 and HDL3 subfractions. Triglyceride levels were lower by 19 mg/dl in the exercise group as compared to the control group (p less than 0.05). We conclude that moderate aerobic exercise of 9 weeks duration in the absence of weight loss in young males with initially low HDL cholesterol did not influence their HDL cholesterol levels.

Adult↗